IW-1701 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sickle Cell Disease
Conditions
Sickle Cell Disease
Trial Timeline
Dec 22, 2017 → Jul 22, 2020
NCT ID
NCT03285178About IW-1701 + Placebo
IW-1701 + Placebo is a phase 2 stage product being developed by Cyclerion Therapeutics for Sickle Cell Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03285178. Target conditions include Sickle Cell Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03285178 | Phase 2 | Completed |
| NCT02792998 | Phase 1 | Completed |
Competing Products
20 competing products in Sickle Cell Disease